首页 > 最新文献

Turkish Thoracic Journal最新文献

英文 中文
The Effect of Vitamin D Deficiency in Chronic Obstructive Pulmonary Disease. 维生素D缺乏对慢性阻塞性肺疾病的影响。
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-05-01 DOI: 10.5152/TurkThoracJ.2021.19108
Hatice Uluçoban, Hülya Dirol, Tülay Özdemir

Objective: It has been suggested that Vitamin D Deficiency (VDD) worsens lung functions and COPD lowers vitamin D levels, but this has not been proven yet.

Material and methods: The study was carried out between January 2014 and September 2015. All the COPD patients with 25 (OH) D3 measurements were included in this study. The patients < 40-year-old, or with a smoking history of less than 10 package-year, or with asthma, bronchiectasis, pneumonia, tuberculosis, cancer, were excluded from the study. Medical records about age, gender, pulmonary function test, body mass index (BMI), annual exacerbations/hospitalizations, modified British Medical Research Council (mMRC) level and serum 25 (OH) D3 were obtained.

Results: The data of 216 (83.8% male) patients were examined in the study. The mean age was 66.88 ± 10.3 years. The mean vitamin D level was 21.1 ± 13.73 ng/mL. Of the patients, 57.9% had VDD, and even 19.9% were in severe VDD. Only 26.4% had adequate vitamin D level. There was a significant in BMI, FEV1, FVC, annual exacerbation and hospitalisations between the patients with vitamin D levels > 20 ng / mL and ≤ 20 ng / mL. Vitamin D level of patients with mMRC level 1 was significantly higher than those with mMRC 2, 3, 4 (respectively P = .03; P = .026; P = .014).

Conclusion: In this study, we found that lung function was worse in COPD patients with VDD and VDD increased with increasing severity of COPD.

目的:已有研究表明,维生素D缺乏(VDD)会使肺功能恶化,而慢性阻塞性肺病(COPD)会降低维生素D水平,但这一点尚未得到证实。材料与方法:研究时间为2014年1月至2015年9月。所有25 (OH) D3检测的COPD患者均纳入本研究。年龄< 40岁,或吸烟史小于10包年,或患有哮喘、支气管扩张、肺炎、肺结核、癌症的患者被排除在研究之外。获得患者的年龄、性别、肺功能检查、体重指数(BMI)、年加重/住院次数、修改后的英国医学研究理事会(mMRC)水平和血清25 (OH) D3等医疗记录。结果:共纳入216例患者,其中男性83.8%。平均年龄66.88±10.3岁。平均维生素D水平为21.1±13.73 ng/mL。57.9%的患者有VDD,其中19.9%为重度VDD。只有26.4%的人有足够的维生素D水平。维生素D水平> 20 ng / mL与≤20 ng / mL患者的BMI、FEV1、FVC、年加重率、住院率差异均有统计学意义,其中维生素D水平为1的患者的维生素D水平显著高于2、3、4的患者(P = .03;P = 0.026;P = .014)。结论:本研究中,我们发现COPD合并VDD患者肺功能较差,且VDD随COPD严重程度的增加而增加。
{"title":"The Effect of Vitamin D Deficiency in Chronic Obstructive Pulmonary Disease.","authors":"Hatice Uluçoban,&nbsp;Hülya Dirol,&nbsp;Tülay Özdemir","doi":"10.5152/TurkThoracJ.2021.19108","DOIUrl":"https://doi.org/10.5152/TurkThoracJ.2021.19108","url":null,"abstract":"<p><strong>Objective: </strong>It has been suggested that Vitamin D Deficiency (VDD) worsens lung functions and COPD lowers vitamin D levels, but this has not been proven yet.</p><p><strong>Material and methods: </strong>The study was carried out between January 2014 and September 2015. All the COPD patients with 25 (OH) D3 measurements were included in this study. The patients < 40-year-old, or with a smoking history of less than 10 package-year, or with asthma, bronchiectasis, pneumonia, tuberculosis, cancer, were excluded from the study. Medical records about age, gender, pulmonary function test, body mass index (BMI), annual exacerbations/hospitalizations, modified British Medical Research Council (mMRC) level and serum 25 (OH) D3 were obtained.</p><p><strong>Results: </strong>The data of 216 (83.8% male) patients were examined in the study. The mean age was 66.88 ± 10.3 years. The mean vitamin D level was 21.1 ± 13.73 ng/mL. Of the patients, 57.9% had VDD, and even 19.9% were in severe VDD. Only 26.4% had adequate vitamin D level. There was a significant in BMI, FEV1, FVC, annual exacerbation and hospitalisations between the patients with vitamin D levels > 20 ng / mL and ≤ 20 ng / mL. Vitamin D level of patients with mMRC level 1 was significantly higher than those with mMRC 2, 3, 4 (respectively P = .03; P = .026; P = .014).</p><p><strong>Conclusion: </strong>In this study, we found that lung function was worse in COPD patients with VDD and VDD increased with increasing severity of COPD.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 3","pages":"242-246"},"PeriodicalIF":0.9,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975311/pdf/ttj-22-3-242.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39881869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Erlotinib or Radiotherapy in the Treatment of Brain Metastasis from EGRF-Mutant NSCLC? 厄洛替尼还是放疗治疗egrf突变NSCLC脑转移?
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-03-01 DOI: 10.5152/TurkThoracJ.2021.20034
Yasemin Benderli Cihan
Mutations in the epidermal growth factor receptor (EGFR) are common in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) are the mainstay of the treatment of patients with EGFR mutations. By inhibiting phosphorylation of intracellular domain of the EGFR, TKIs disrupt signal transduction in the ras/eaf/MAPK and PI3K/Akt pathways, which are known to play important roles in cell growth and proliferation, angiogenesis, tumor invasion, and metastasis. In nonselected patients with NSCLC, TKIs achieved a 10% response in the EGFR. Thus, patient populations who benefited from these agents were investigated, and high response rates and long survival times were achieved with both firstand secondline therapies in specific subgroups [1-3].
{"title":"Erlotinib or Radiotherapy in the Treatment of Brain Metastasis from EGRF-Mutant NSCLC?","authors":"Yasemin Benderli Cihan","doi":"10.5152/TurkThoracJ.2021.20034","DOIUrl":"10.5152/TurkThoracJ.2021.20034","url":null,"abstract":"Mutations in the epidermal growth factor receptor (EGFR) are common in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) are the mainstay of the treatment of patients with EGFR mutations. By inhibiting phosphorylation of intracellular domain of the EGFR, TKIs disrupt signal transduction in the ras/eaf/MAPK and PI3K/Akt pathways, which are known to play important roles in cell growth and proliferation, angiogenesis, tumor invasion, and metastasis. In nonselected patients with NSCLC, TKIs achieved a 10% response in the EGFR. Thus, patient populations who benefited from these agents were investigated, and high response rates and long survival times were achieved with both firstand secondline therapies in specific subgroups [1-3].","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 2","pages":"184-185"},"PeriodicalIF":0.9,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051289/pdf/ttj-22-2-184.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38887767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Excess Mortality During COVID-19 Pandemic in İstanbul. COVID-19大流行期间的超额死亡率:İstanbul。
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-03-01 DOI: 10.5152/TurkThoracJ.2021.20258
Benan Musellim, Seval Kul, Pınar Ay, Filiz Çağla Uyanusta Küçük, Elif Dağlı, Oya Itil, Hasan Bayram

Objective: Epidemiological studies have shown that mortality owing to the coronavirus disease 2019 (COVID-19) could be under-reported under different conditions. Excess mortality analysis is suggested as a useful tool in estimating the impact of the disease.

Material and methods: Mortality data between January 01 and May 18, 2020, were analyzed to evaluate the excess mortality owing to COVID-19 in Istanbul, the city most affected by the pandemic in Turkey. The average weekly percentage changes in the number of deaths in 4 previous years were compared with those in the year 2020 using excess mortality analysis.

Results: The number of deaths in Istanbul was significantly higher in 2020 (p=0.001), with a 10% weekly increase between the 10th and 15th weeks, which started to decrease until the 20th week. The excess mortality found during the study period was 4,084 deaths, higher than the officially reported COVID-19 mortality.

Conclusion: Our findings demonstrated that mortality owing to COVID-19 could be higher than the official figures reported by health authorities.

目的:流行病学研究表明,2019冠状病毒病(COVID-19)的死亡率在不同情况下可能存在低报现象。建议将超额死亡率分析作为估计该病影响的有用工具。材料和方法:分析2020年1月1日至5月18日的死亡率数据,以评估土耳其受疫情影响最严重的城市伊斯坦布尔因COVID-19造成的超额死亡率。利用超额死亡率分析,将前4年死亡人数的平均每周百分比变化与2020年的死亡人数进行了比较。结果:伊斯坦布尔的死亡人数在2020年显著增加(p=0.001),在第10周至第15周期间每周增加10%,直到第20周开始下降。在研究期间发现的超额死亡率为4084人,高于官方报告的COVID-19死亡率。结论:我们的研究结果表明,COVID-19的死亡率可能高于卫生当局报告的官方数字。
{"title":"Excess Mortality During COVID-19 Pandemic in İstanbul.","authors":"Benan Musellim,&nbsp;Seval Kul,&nbsp;Pınar Ay,&nbsp;Filiz Çağla Uyanusta Küçük,&nbsp;Elif Dağlı,&nbsp;Oya Itil,&nbsp;Hasan Bayram","doi":"10.5152/TurkThoracJ.2021.20258","DOIUrl":"https://doi.org/10.5152/TurkThoracJ.2021.20258","url":null,"abstract":"<p><strong>Objective: </strong>Epidemiological studies have shown that mortality owing to the coronavirus disease 2019 (COVID-19) could be under-reported under different conditions. Excess mortality analysis is suggested as a useful tool in estimating the impact of the disease.</p><p><strong>Material and methods: </strong>Mortality data between January 01 and May 18, 2020, were analyzed to evaluate the excess mortality owing to COVID-19 in Istanbul, the city most affected by the pandemic in Turkey. The average weekly percentage changes in the number of deaths in 4 previous years were compared with those in the year 2020 using excess mortality analysis.</p><p><strong>Results: </strong>The number of deaths in Istanbul was significantly higher in 2020 (p=0.001), with a 10% weekly increase between the 10th and 15th weeks, which started to decrease until the 20th week. The excess mortality found during the study period was 4,084 deaths, higher than the officially reported COVID-19 mortality.</p><p><strong>Conclusion: </strong>Our findings demonstrated that mortality owing to COVID-19 could be higher than the official figures reported by health authorities.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 2","pages":"137-141"},"PeriodicalIF":0.9,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051305/pdf/ttj-22-2-137.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38888227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Managing Lung Cancer during Coronavirus Disease 2019 Pandemic. 2019冠状病毒病大流行期间的肺癌管理。
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-03-01 DOI: 10.5152/TurkThoracJ.2021.20110
Yara Ibrahim Khalifeh, Arafat Hussein Tfayli

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared as a pandemic by the World Health Organization. As this disease continues to spread worldwide, it has posed enormous challenges on the healthcare of several diseases, especially cancer, because hospital facilities have invested health resources for patients with COVID-19. Indeed, patients with lung cancer are particularly vulnerable because of their poor baseline lung function and cancer-related treatment. In addition, once infected, they are at an increased risk of pulmonary complications from COVID-19. Oncologists are thus facing a challenge as how to balance the treatment plans to control the disease while protecting the patients with lung cancer from COVID-19. In fact, it is crucial to provide individualized treatment recommendations to limit the risks during these difficult times. This review highlights the key challenges that oncologists face when diagnosing COVID-19 among patients with lung cancer and examines the current recommendations from available literature, clinical expertise, and expert opinions regarding managing lung cancer in the era of COVID-19. It also explores the treatment approach recommended for patients with lung cancer while avoiding putting them at excessive risk of contracting COVID-19 infection.

由严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2)引起的冠状病毒病2019 (COVID-19)已被世界卫生组织宣布为大流行。随着这种疾病继续在全球传播,它给几种疾病的医疗保健带来了巨大挑战,特别是癌症,因为医院设施为COVID-19患者投入了卫生资源。事实上,肺癌患者尤其容易受到伤害,因为他们的基线肺功能和癌症相关治疗都很差。此外,一旦感染,他们患COVID-19肺部并发症的风险会增加。因此,如何平衡治疗方案,既能控制疾病,又能保护肺癌患者免受COVID-19的感染,这是肿瘤学家面临的挑战。事实上,在这些困难时期,提供个性化的治疗建议以限制风险是至关重要的。本综述强调了肿瘤学家在肺癌患者中诊断COVID-19时面临的主要挑战,并从现有文献、临床专业知识和专家意见中研究了当前关于COVID-19时代管理肺癌的建议。它还探讨了建议肺癌患者的治疗方法,同时避免将他们置于感染新冠病毒的过度风险中。
{"title":"Managing Lung Cancer during Coronavirus Disease 2019 Pandemic.","authors":"Yara Ibrahim Khalifeh, Arafat Hussein Tfayli","doi":"10.5152/TurkThoracJ.2021.20110","DOIUrl":"10.5152/TurkThoracJ.2021.20110","url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared as a pandemic by the World Health Organization. As this disease continues to spread worldwide, it has posed enormous challenges on the healthcare of several diseases, especially cancer, because hospital facilities have invested health resources for patients with COVID-19. Indeed, patients with lung cancer are particularly vulnerable because of their poor baseline lung function and cancer-related treatment. In addition, once infected, they are at an increased risk of pulmonary complications from COVID-19. Oncologists are thus facing a challenge as how to balance the treatment plans to control the disease while protecting the patients with lung cancer from COVID-19. In fact, it is crucial to provide individualized treatment recommendations to limit the risks during these difficult times. This review highlights the key challenges that oncologists face when diagnosing COVID-19 among patients with lung cancer and examines the current recommendations from available literature, clinical expertise, and expert opinions regarding managing lung cancer in the era of COVID-19. It also explores the treatment approach recommended for patients with lung cancer while avoiding putting them at excessive risk of contracting COVID-19 infection.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 2","pages":"163-168"},"PeriodicalIF":0.9,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051296/pdf/ttj-22-2-163.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38888231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Use of Medical Thoracoscopy for Retrieval of Broken Intrapleural Catheter. 医用胸腔镜在胸膜内导管破裂取出中的应用。
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-03-01 DOI: 10.5152/TurkThoracJ.2021.19120
Kamran Khan Sumalani, Uneeba Rehman, Nousheen Akhter, Nadeem Ahmed Rizvi

Small-bore pleural catheters are used to drain simple effusions effectively. They are less invasive and more comfortable than tube thoracostomy. As with any other intervention, these small catheters have their associated complications. Herein, we report a case of a young woman who was diagnosed with tuberculous pleural effusion. Easydrain pleural catheter was inserted to drain the effusion; it broke in situ because of improper insertion and was later removed using medical thoracoscopy. We emphasize on the need for proper training for doctors and staff regarding these procedures to avoid undue complications. We have also highlighted the importance of medical thoracoscopy in the removal of retained intrapleural foreign bodies.

小口径胸膜导管可有效引流单纯积液。它们比管式开胸术侵入性更小,更舒适。与任何其他干预一样,这些小导管有其相关的并发症。在此,我们报告一个年轻女性被诊断为结核性胸腔积液的病例。置入易排胸膜导管引流积液;由于插入不当,它在原位断裂,后来通过医学胸腔镜切除。我们强调需要对医生和工作人员进行适当的培训,以避免不必要的并发症。我们还强调了医学胸腔镜在去除保留的胸膜内异物中的重要性。
{"title":"Use of Medical Thoracoscopy for Retrieval of Broken Intrapleural Catheter.","authors":"Kamran Khan Sumalani,&nbsp;Uneeba Rehman,&nbsp;Nousheen Akhter,&nbsp;Nadeem Ahmed Rizvi","doi":"10.5152/TurkThoracJ.2021.19120","DOIUrl":"https://doi.org/10.5152/TurkThoracJ.2021.19120","url":null,"abstract":"<p><p>Small-bore pleural catheters are used to drain simple effusions effectively. They are less invasive and more comfortable than tube thoracostomy. As with any other intervention, these small catheters have their associated complications. Herein, we report a case of a young woman who was diagnosed with tuberculous pleural effusion. Easydrain pleural catheter was inserted to drain the effusion; it broke in situ because of improper insertion and was later removed using medical thoracoscopy. We emphasize on the need for proper training for doctors and staff regarding these procedures to avoid undue complications. We have also highlighted the importance of medical thoracoscopy in the removal of retained intrapleural foreign bodies.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 2","pages":"179-181"},"PeriodicalIF":0.9,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051304/pdf/ttj-22-2-179.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38887765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Evaluation of Patients with Fibrotic Interstitial Lung Disease: Preliminary results from the Turk-UIP Study. 纤维化间质性肺病患者的评估:土耳其- uip研究的初步结果
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-03-01 DOI: 10.5152/TurkThoracJ.2021.20028
Musellim Benan, Mogulkoc Nesrin, Uzun Oguz, Tokgoz Akyil Fatma, Turktas Haluk, Ozdemir Kumbasar Ozlem, Okumus Gulfer, Ogus Candan, Dirol Hulya, Zamani Adil, Sevim Tulin, Annakkaya Ali Nihat, Ozyurek Berna Akinci, Hanta Ismail, Aydemir Yusuf, Cakir Edis Ebru, Kurt Bahar, Tertemiz Kemal Can, Tabak Levent, Yazici Onur, Erdogan Yurdanur, Ates Gungor, Turker Hatice, Salepci Banu, Hazar Armagan, Niksarlioglu Elif Yelda, Yılmaz Kara Bilge, Kokturk Nurdan, Kalpaklioglu Fusun, Uzel Isil, Ozsu Savas, Atahan Ersan, Fendoglu Turkan Zeynep, Yilmaz Sureyya, Basyigit Ilknur, Camsari Gungor, Tuncay Esin, Ucar Yilmazel Elif, Kanmaz Dilek, Ekici Aydanur, Topcu Fusun, Uzaslan Esra, Bozkus Fulsen, Argun Baris Serap, Duru Serap, Altinisik Goksel, Bingol Zuleyha, Tunaci Atadan, Savas Recep, Alper Fatih, Bayraktaroglu Selen, Selcuk Can Tuba, Demir Ali Arslan

Objective: Differential diagnosis of idiopathic pulmonary fibrosis (IPF) is important among fibrotic interstitial lung diseases (ILD). This study aimed to evaluate the rate of IPF in patients with fibrotic ILD and to determine the clinical-laboratory features of patients with and without IPF that would provide the differential diagnosis of IPF.

Material and methods: The study included the patients with the usual interstitial pneumonia (UIP) pattern or possible UIP pattern on thorax high-resolution computed tomography, and/or UIP pattern, probable UIP or possible UIP pattern at lung biopsy according to the 2011 ATS/ERS/JRS/ALAT guidelines. Demographics and clinical and radiological data of the patients were recorded. All data recorded by researchers was evaluated by radiology and the clinical decision board.

Results: A total of 336 patients (253 men, 83 women, age 65.8±9.0 years) were evaluated. Of the patients with sufficient data for diagnosis (n=300), the diagnosis was IPF in 121 (40.3%), unclassified idiopathic interstitial pneumonia in 50 (16.7%), combined pulmonary fibrosis and emphysema (CPFE) in 40 (13.3%), and lung involvement of connective tissue disease (CTD) in 16 (5.3%). When 29 patients with definite IPF features were added to the patients with CPFE, the total number of IPF patients reached 150 (50%). Rate of male sex (p<0.001), smoking history (p<0.001), and the presence of clubbing (p=0.001) were significantly high in patients with IPF. None of the women <50 years and none of the men <50 years of age without a smoking history were diagnosed with IPF. Presence of at least 1 of the symptoms suggestive of CTD, erythrocyte sedimentation rate (ESR), and antinuclear antibody (FANA) positivity rates were significantly higher in the non-IPF group (p<0.001, p=0.029, p=0.009, respectively).

Conclusion: The rate of IPF among patients with fibrotic ILD was 50%. In the differential diagnosis of IPF, sex, smoking habits, and the presence of clubbing are important. The presence of symptoms related to CTD, ESR elevation, and FANA positivity reduce the likelihood of IPF.

目的:特发性肺纤维化(IPF)的鉴别诊断在纤维化间质性肺疾病(ILD)中具有重要意义。本研究旨在评估纤维化性ILD患者的IPF发生率,并确定有和无IPF患者的临床-实验室特征,以提供IPF的鉴别诊断。材料和方法:本研究纳入了根据2011年ATS/ERS/JRS/ALAT指南在胸部高分辨率计算机断层扫描上表现为通常间质性肺炎(UIP)或可能的UIP型,和/或肺活检表现为UIP型、可能的UIP型或可能的UIP型的患者。记录患者的人口统计学、临床和放射学资料。研究人员记录的所有数据均由放射学和临床决策委员会进行评估。结果:共纳入336例患者,其中男性253例,女性83例,年龄65.8±9.0岁。在有足够诊断资料的患者中(n=300),诊断为IPF 121例(40.3%),未分类特发性间质性肺炎50例(16.7%),合并肺纤维化和肺气肿(CPFE) 40例(13.3%),肺部累及结缔组织病(CTD) 16例(5.3%)。在CPFE患者中加上29例明确IPF特征的患者,IPF患者总数达到150例(50%)。结论:纤维化性ILD患者IPF发生率为50%。在IPF的鉴别诊断中,性别、吸烟习惯和俱乐部的存在是重要的。与CTD、ESR升高和FANA阳性相关的症状的存在降低了IPF的可能性。
{"title":"Evaluation of Patients with Fibrotic Interstitial Lung Disease: Preliminary results from the Turk-UIP Study.","authors":"Musellim Benan,&nbsp;Mogulkoc Nesrin,&nbsp;Uzun Oguz,&nbsp;Tokgoz Akyil Fatma,&nbsp;Turktas Haluk,&nbsp;Ozdemir Kumbasar Ozlem,&nbsp;Okumus Gulfer,&nbsp;Ogus Candan,&nbsp;Dirol Hulya,&nbsp;Zamani Adil,&nbsp;Sevim Tulin,&nbsp;Annakkaya Ali Nihat,&nbsp;Ozyurek Berna Akinci,&nbsp;Hanta Ismail,&nbsp;Aydemir Yusuf,&nbsp;Cakir Edis Ebru,&nbsp;Kurt Bahar,&nbsp;Tertemiz Kemal Can,&nbsp;Tabak Levent,&nbsp;Yazici Onur,&nbsp;Erdogan Yurdanur,&nbsp;Ates Gungor,&nbsp;Turker Hatice,&nbsp;Salepci Banu,&nbsp;Hazar Armagan,&nbsp;Niksarlioglu Elif Yelda,&nbsp;Yılmaz Kara Bilge,&nbsp;Kokturk Nurdan,&nbsp;Kalpaklioglu Fusun,&nbsp;Uzel Isil,&nbsp;Ozsu Savas,&nbsp;Atahan Ersan,&nbsp;Fendoglu Turkan Zeynep,&nbsp;Yilmaz Sureyya,&nbsp;Basyigit Ilknur,&nbsp;Camsari Gungor,&nbsp;Tuncay Esin,&nbsp;Ucar Yilmazel Elif,&nbsp;Kanmaz Dilek,&nbsp;Ekici Aydanur,&nbsp;Topcu Fusun,&nbsp;Uzaslan Esra,&nbsp;Bozkus Fulsen,&nbsp;Argun Baris Serap,&nbsp;Duru Serap,&nbsp;Altinisik Goksel,&nbsp;Bingol Zuleyha,&nbsp;Tunaci Atadan,&nbsp;Savas Recep,&nbsp;Alper Fatih,&nbsp;Bayraktaroglu Selen,&nbsp;Selcuk Can Tuba,&nbsp;Demir Ali Arslan","doi":"10.5152/TurkThoracJ.2021.20028","DOIUrl":"https://doi.org/10.5152/TurkThoracJ.2021.20028","url":null,"abstract":"<p><strong>Objective: </strong>Differential diagnosis of idiopathic pulmonary fibrosis (IPF) is important among fibrotic interstitial lung diseases (ILD). This study aimed to evaluate the rate of IPF in patients with fibrotic ILD and to determine the clinical-laboratory features of patients with and without IPF that would provide the differential diagnosis of IPF.</p><p><strong>Material and methods: </strong>The study included the patients with the usual interstitial pneumonia (UIP) pattern or possible UIP pattern on thorax high-resolution computed tomography, and/or UIP pattern, probable UIP or possible UIP pattern at lung biopsy according to the 2011 ATS/ERS/JRS/ALAT guidelines. Demographics and clinical and radiological data of the patients were recorded. All data recorded by researchers was evaluated by radiology and the clinical decision board.</p><p><strong>Results: </strong>A total of 336 patients (253 men, 83 women, age 65.8±9.0 years) were evaluated. Of the patients with sufficient data for diagnosis (n=300), the diagnosis was IPF in 121 (40.3%), unclassified idiopathic interstitial pneumonia in 50 (16.7%), combined pulmonary fibrosis and emphysema (CPFE) in 40 (13.3%), and lung involvement of connective tissue disease (CTD) in 16 (5.3%). When 29 patients with definite IPF features were added to the patients with CPFE, the total number of IPF patients reached 150 (50%). Rate of male sex (p<0.001), smoking history (p<0.001), and the presence of clubbing (p=0.001) were significantly high in patients with IPF. None of the women <50 years and none of the men <50 years of age without a smoking history were diagnosed with IPF. Presence of at least 1 of the symptoms suggestive of CTD, erythrocyte sedimentation rate (ESR), and antinuclear antibody (FANA) positivity rates were significantly higher in the non-IPF group (p<0.001, p=0.029, p=0.009, respectively).</p><p><strong>Conclusion: </strong>The rate of IPF among patients with fibrotic ILD was 50%. In the differential diagnosis of IPF, sex, smoking habits, and the presence of clubbing are important. The presence of symptoms related to CTD, ESR elevation, and FANA positivity reduce the likelihood of IPF.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 2","pages":"102-109"},"PeriodicalIF":0.9,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051299/pdf/ttj-22-2-102.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38892824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Determining Tracheobronchial Tree with Anatomical Dissection: 204 Cases. 解剖解剖法确定气管支气管树204例。
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-03-01 DOI: 10.5152/TurkThoracJ.2021.18111
Aysun Akdeniz, Erdoğan Kara

Objectives: There are various anatomic variations in the tracheobronchial system. The frequency in studies with bronchoscopy was contradictory. This study aimed to investigate the tracheobronchial tree of the deceased patients with anatomical dissection.

Material and methods: We made anatomical dissections on 204 cases in the Council of Forensic Medicine, Ministry of Justice. The deceased patients who were older than 12 years of age and of Turkish origin were included in this study consecutively.

Results: Of the 204 cases, 161 (78.9%) were males and 43 (21.1%) were females. The mean age was 44.15±19.23 years. Anatomical variations were found to be present in 200 cases (98% of total). The highest degree of variation of the right upper lobe was noted to be 16.6% (34/204). An anomalous arrangement (with three segments or different placement) of the middle lobe was noted in 16.1% of cases. For the basal lower lobe, b8+(b9+b10) pattern and basal orifice with four segments were noted to be the most frequent anatomical variant in the right and left lungs, respectively. The most frequent tracheobronchial variations were as follows: apical basal lobe with two subsegments in the right and left (39.7%), left lower lobe basal orifice with four segments (34.8%), left upper lobe with three segments (25.5%), and right lower lobe basal orifice with three main segmental bronchi (21.1%).

Conclusion: The tracheobronchial tree exhibits highly individualistic features. The knowledge of the frequency of different variations obtained in different studies and normal anatomic variants in return makes doing therapeutic or diagnostic interventions easier and more accurate.

目的:气管支气管系统存在多种解剖变异。支气管镜检查的频率是矛盾的。本研究的目的是通过解剖解剖研究死者的气管支气管树。材料与方法:对司法部法医学委员会204例病例进行解剖解剖。年龄大于12岁且土耳其裔的死亡患者被连续纳入本研究。结果:204例患者中,男性161例(78.9%),女性43例(21.1%)。平均年龄44.15±19.23岁。在200例(占总数的98%)中发现解剖变异。右上叶最大变异程度为16.6%(34/204)。在16.1%的病例中发现了中叶的异常排列(有三个节段或不同的位置)。对于基底下叶,b8+(b9+b10)模式和基底孔四节段分别是右肺和左肺最常见的解剖变异。最常见的气管支气管变异为:根底叶有左右两个亚段(39.7%),左下叶基孔有四个段(34.8%),左上叶基孔有三个段(25.5%),右下叶基孔有三个主支气管段(21.1%)。结论:气管支气管树具有高度的个体特征。在不同的研究中获得的不同变异频率的知识和正常的解剖变异反过来使治疗或诊断干预更容易和更准确。
{"title":"Determining Tracheobronchial Tree with Anatomical Dissection: 204 Cases.","authors":"Aysun Akdeniz,&nbsp;Erdoğan Kara","doi":"10.5152/TurkThoracJ.2021.18111","DOIUrl":"https://doi.org/10.5152/TurkThoracJ.2021.18111","url":null,"abstract":"<p><strong>Objectives: </strong>There are various anatomic variations in the tracheobronchial system. The frequency in studies with bronchoscopy was contradictory. This study aimed to investigate the tracheobronchial tree of the deceased patients with anatomical dissection.</p><p><strong>Material and methods: </strong>We made anatomical dissections on 204 cases in the Council of Forensic Medicine, Ministry of Justice. The deceased patients who were older than 12 years of age and of Turkish origin were included in this study consecutively.</p><p><strong>Results: </strong>Of the 204 cases, 161 (78.9%) were males and 43 (21.1%) were females. The mean age was 44.15±19.23 years. Anatomical variations were found to be present in 200 cases (98% of total). The highest degree of variation of the right upper lobe was noted to be 16.6% (34/204). An anomalous arrangement (with three segments or different placement) of the middle lobe was noted in 16.1% of cases. For the basal lower lobe, b8+(b9+b10) pattern and basal orifice with four segments were noted to be the most frequent anatomical variant in the right and left lungs, respectively. The most frequent tracheobronchial variations were as follows: apical basal lobe with two subsegments in the right and left (39.7%), left lower lobe basal orifice with four segments (34.8%), left upper lobe with three segments (25.5%), and right lower lobe basal orifice with three main segmental bronchi (21.1%).</p><p><strong>Conclusion: </strong>The tracheobronchial tree exhibits highly individualistic features. The knowledge of the frequency of different variations obtained in different studies and normal anatomic variants in return makes doing therapeutic or diagnostic interventions easier and more accurate.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 2","pages":"124-129"},"PeriodicalIF":0.9,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051302/pdf/ttj-22-2-124.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38888225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 Screening Program Should be Performed in Healthcare Workers. 应在医护人员中实施COVID-19筛查计划。
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-03-01 DOI: 10.5152/TurkThoracJ.2021.20217
Necati Çitak, Atilla Pekçolaklar

The screening test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) disease 2019 (COVID-19) has not been performed in healthcare workers (HCWs) yet, although HCWs are at a high risk of infection. COVID-19 is detected in 5%-15% of HCWs according to published studies. Nevertheless, it may be higher than the rates indicated in published studies. Based on this fact, the current recommendation of studies in the literature is to screen COVID-19 in HCWs. In this review, studies on SARS-CoV-2 screening in HCWs will be reconsidered, and the frequency and target group in whom screening should be performed will be emphasized.

尽管卫生保健工作者(HCWs)的感染风险很高,但尚未对其进行2019年严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2)病(COVID-19)筛查试验。根据已发表的研究,在5%-15%的卫生保健工作者中检测到COVID-19。然而,它可能比发表的研究表明的比率要高。基于这一事实,目前文献中的研究建议是在医护人员中筛查COVID-19。在这篇综述中,将重新考虑在卫生保健工作者中进行SARS-CoV-2筛查的研究,并强调筛查的频率和目标人群。
{"title":"COVID-19 Screening Program Should be Performed in Healthcare Workers.","authors":"Necati Çitak,&nbsp;Atilla Pekçolaklar","doi":"10.5152/TurkThoracJ.2021.20217","DOIUrl":"https://doi.org/10.5152/TurkThoracJ.2021.20217","url":null,"abstract":"<p><p>The screening test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) disease 2019 (COVID-19) has not been performed in healthcare workers (HCWs) yet, although HCWs are at a high risk of infection. COVID-19 is detected in 5%-15% of HCWs according to published studies. Nevertheless, it may be higher than the rates indicated in published studies. Based on this fact, the current recommendation of studies in the literature is to screen COVID-19 in HCWs. In this review, studies on SARS-CoV-2 screening in HCWs will be reconsidered, and the frequency and target group in whom screening should be performed will be emphasized.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 2","pages":"169-174"},"PeriodicalIF":0.9,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051292/pdf/ttj-22-2-169.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38887763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Outcomes in Pulmonary Hypertension in Relation to Insurance Status: National Hospital Discharge Survey, 2000-2010. 肺动脉高压的治疗结果与保险状况的关系:2000-2010年全国出院调查。
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-03-01 DOI: 10.5152/TurkThoracJ.2021.19163
Srikanta Banerjee, Alessandro Puddu
{"title":"Outcomes in Pulmonary Hypertension in Relation to Insurance Status: National Hospital Discharge Survey, 2000-2010.","authors":"Srikanta Banerjee, Alessandro Puddu","doi":"10.5152/TurkThoracJ.2021.19163","DOIUrl":"10.5152/TurkThoracJ.2021.19163","url":null,"abstract":"","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 2","pages":"182-183"},"PeriodicalIF":0.9,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051291/pdf/ttj-22-2-182.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38887766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Barotrauma in Patients with COVID-19 Infection on Invasive Mechanical Ventilation. 有创机械通气对COVID-19感染患者气压创伤的影响
IF 0.9 Q4 RESPIRATORY SYSTEM Pub Date : 2021-03-01 DOI: 10.5152/TurkThoracJ.2021.20209
Hakan Abdullah Özgül, Naciye Sinem Gezer, Begüm Ergan, Ali Necati Gökmen
The novel coronavirus defined as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first identified in Wuhan, China, in December 2019 and spread worldwide from there [1]. The World Health Organization named the disease caused by SARS-CoV-2 the coronavirus disease 2019 (COVID-19) and declared this outbreak a pandemic in March 2020 [2]. The first case in Turkey was officially announced on March 10, 2020 [3].
{"title":"Barotrauma in Patients with COVID-19 Infection on Invasive Mechanical Ventilation.","authors":"Hakan Abdullah Özgül,&nbsp;Naciye Sinem Gezer,&nbsp;Begüm Ergan,&nbsp;Ali Necati Gökmen","doi":"10.5152/TurkThoracJ.2021.20209","DOIUrl":"https://doi.org/10.5152/TurkThoracJ.2021.20209","url":null,"abstract":"The novel coronavirus defined as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first identified in Wuhan, China, in December 2019 and spread worldwide from there [1]. The World Health Organization named the disease caused by SARS-CoV-2 the coronavirus disease 2019 (COVID-19) and declared this outbreak a pandemic in March 2020 [2]. The first case in Turkey was officially announced on March 10, 2020 [3].","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"22 2","pages":"188-189"},"PeriodicalIF":0.9,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051303/pdf/ttj-22-2-188.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38887769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Turkish Thoracic Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1